156 related articles for article (PubMed ID: 36538914)
1. The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition.
Masjedi M; Azadikhah S; Zand F; Asmarian N; Sabetian G; Ostovan M; Naderi-Boldaji V
Acta Haematol; 2023; 146(2):137-143. PubMed ID: 36538914
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin for venous thromboembolism prophylaxis in general Intensive Care Unit patients: an anti-factor Xa level-based approach.
Zohar N; Ellis MH; Dichtwald S; Meyer A; Zohar E; Ifrach N
Minerva Anestesiol; 2023 May; 89(5):425-433. PubMed ID: 36326777
[TBL] [Abstract][Full Text] [Related]
3. Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19.
Hamilton DO; Main-Ian A; Tebbutt J; Thrasher M; Waite A; Welters I
Thromb J; 2021 Nov; 19(1):87. PubMed ID: 34781984
[TBL] [Abstract][Full Text] [Related]
4. Bioactivity of enoxaparin in critically ill patients with normal renal function.
Gouya G; Palkovits S; Kapiotis S; Madl C; Locker G; Stella A; Wolzt M; Heinz G
Br J Clin Pharmacol; 2012 Nov; 74(5):806-14. PubMed ID: 23227470
[TBL] [Abstract][Full Text] [Related]
5. Plasma anti-FXa level as a surrogate marker of the adequacy of thromboprophylaxis in critically ill patients: A systematic review.
Vahtera A; Vaara S; Pettilä V; Kuitunen A
Thromb Res; 2016 Mar; 139():10-6. PubMed ID: 26916290
[TBL] [Abstract][Full Text] [Related]
6. Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019.
Mohamed A; Shemanski SM; Saad MO; Ploetz J; Haines MM; Schlachter AB; Hamarshi MS
Clin Appl Thromb Hemost; 2022; 28():10760296221116350. PubMed ID: 35924413
[No Abstract] [Full Text] [Related]
7. Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study.
Benes J; Skulec R; Jobanek J; Cerny V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 May; 166(2):204-210. PubMed ID: 34042098
[TBL] [Abstract][Full Text] [Related]
8. Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study.
Miranda S; Le Cam-Duchez V; Benichou J; Donnadieu N; Barbay V; Le Besnerais M; Delmas FX; Cuvelier A; Lévesque H; Benhamou Y; Armengol G
Thromb Res; 2017 Jul; 155():1-5. PubMed ID: 28460259
[TBL] [Abstract][Full Text] [Related]
9. Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial.
Vahtera A; Valkonen M; Huhtala H; Pettilä V; Kuitunen A
Thromb Res; 2017 Oct; 158():71-75. PubMed ID: 28846877
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
[TBL] [Abstract][Full Text] [Related]
11. Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.
Cosmi B; Giannella M; Fornaro G; Cristini F; Patacca A; Castagna A; Mazzaferri F; Testa S; Pan A; Lupi M; Brambilla P; Montineri A; Frattima S; Bignami EG; Salvetti M; De Stefano G; Grandone E; Di Perri G; Rozzini R; Stella A; Romagnoli A; Drago F; Viale P
BMC Infect Dis; 2023 Oct; 23(1):718. PubMed ID: 37875792
[TBL] [Abstract][Full Text] [Related]
12. Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients.
de Maat MMR; van Leeuwen HJ; Roovers L; Ahlers SJGM; Lambers J; Hovens MMC
BMC Pharmacol Toxicol; 2024 Feb; 25(1):16. PubMed ID: 38321487
[TBL] [Abstract][Full Text] [Related]
13. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
[TBL] [Abstract][Full Text] [Related]
14. Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients.
Singer GA; Riggi G; Karcutskie CA; Vaghaiwalla TM; Lieberman HM; Ginzburg E; Namias N; Lineen EB
J Trauma Acute Care Surg; 2016 Dec; 81(6):1101-1108. PubMed ID: 27488490
[TBL] [Abstract][Full Text] [Related]
15. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
[TBL] [Abstract][Full Text] [Related]
16. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
[TBL] [Abstract][Full Text] [Related]
17. Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children.
Greene LA; Law C; Jung M; Walton S; Ignjatovic V; Monagle P; Raffini LJ
J Thromb Haemost; 2014 Sep; 12(9):1554-7. PubMed ID: 24943261
[TBL] [Abstract][Full Text] [Related]
18. Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients.
Stattin K; Lipcsey M; Andersson H; Pontén E; Bülow Anderberg S; Gradin A; Larsson A; Lubenow N; von Seth M; Rubertsson S; Hultström M; Frithiof R
J Crit Care; 2020 Dec; 60():249-252. PubMed ID: 32920503
[TBL] [Abstract][Full Text] [Related]
19. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
Albertsen IE; Larsen TB; Rasmussen LH; Overvad TF; Lip GY
Drugs; 2012 Sep; 72(13):1755-64. PubMed ID: 22876779
[TBL] [Abstract][Full Text] [Related]
20. Anti-factor X activity levels with continuous intravenous infusion and subcutaneous administration of enoxaparin after coronary artery bypass grafting: A randomized clinical trial.
Parviainen MK; Vahtera A; Ånäs N; Tähtinen J; Huhtala H; Kuitunen A; Järvelä K
Acta Anaesthesiol Scand; 2022 Oct; 66(9):1083-1090. PubMed ID: 35908159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
